Christopher R Bradley1,2, Eleanor F Cox1,2, Naaventhan Palaniyappan1,3, Susan T Francis1,2, Indra Neil Guha4,5, Guruprasad P Aithal1,3. 1. NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK. 2. Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK. 3. Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK. 4. NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK. Neil.Guha@nottingham.ac.uk. 5. Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK. Neil.Guha@nottingham.ac.uk.
Abstract
BACKGROUND: We annually monitored stable compensated cirrhosis (CC) patients to evaluate serial variation in blood serum, liver stiffness, and multiparametric magnetic resonance imaging (mpMRI) measures to provide reference change values (RCV) and sample size measures for future studies. METHODS: Patients were recruited from a prospectively followed CC cohort, with assessments at baseline and annually over three years. We report on blood markers, transient elastography liver stiffness measures (LSM) and noninvasive mpMRI (volume, T1 mapping, blood flow, perfusion) of the liver, spleen, kidneys, and heart in a stable CC group and a healthy volunteer (HV) group. Coefficient of variation over time (CoVT) and RCV are reported, along with hazard ratio to assess disease progression. Sample size estimates to power future trials of cirrhosis regression on mpMRI are presented. RESULTS: Of 60 CC patients enrolled, 28 with stable CC were followed longitudinally and compared to 10 HVs. CoVT in mpMRI measures was comparable between CC and HV groups. CoVT of Enhanced Liver Fibrosis score was low (< 5%) compared to Fibrosis-4 index (17.9%) and Aspartate Aminotransferase-to-Platelet-Ratio Index (19.4%). A large CoVT (20.7%) and RCV (48.3%) were observed for LSM. CoVT and RCV were low for liver, spleen, and renal T1 values (CoVT < 5%, RCV < 8%) and volume (CoVT < 10%, RCV < 16%); haemodynamic measures were high (CoVT 12-25%, RCV 16-47%). CONCLUSIONS: Evidence of low CoVT and RCV in multiorgan T1 values. RCV and sample size estimates are provided for future longitudinal multiorgan monitoring in CC patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02037867 , Registered: 05/01/2013.
BACKGROUND: We annually monitored stable compensated cirrhosis (CC) patients to evaluate serial variation in blood serum, liver stiffness, and multiparametric magnetic resonance imaging (mpMRI) measures to provide reference change values (RCV) and sample size measures for future studies. METHODS: Patients were recruited from a prospectively followed CC cohort, with assessments at baseline and annually over three years. We report on blood markers, transient elastography liver stiffness measures (LSM) and noninvasive mpMRI (volume, T1 mapping, blood flow, perfusion) of the liver, spleen, kidneys, and heart in a stable CC group and a healthy volunteer (HV) group. Coefficient of variation over time (CoVT) and RCV are reported, along with hazard ratio to assess disease progression. Sample size estimates to power future trials of cirrhosis regression on mpMRI are presented. RESULTS: Of 60 CC patients enrolled, 28 with stable CC were followed longitudinally and compared to 10 HVs. CoVT in mpMRI measures was comparable between CC and HV groups. CoVT of Enhanced Liver Fibrosis score was low (< 5%) compared to Fibrosis-4 index (17.9%) and Aspartate Aminotransferase-to-Platelet-Ratio Index (19.4%). A large CoVT (20.7%) and RCV (48.3%) were observed for LSM. CoVT and RCV were low for liver, spleen, and renal T1 values (CoVT < 5%, RCV < 8%) and volume (CoVT < 10%, RCV < 16%); haemodynamic measures were high (CoVT 12-25%, RCV 16-47%). CONCLUSIONS: Evidence of low CoVT and RCV in multiorgan T1 values. RCV and sample size estimates are provided for future longitudinal multiorgan monitoring in CC patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02037867 , Registered: 05/01/2013.
Authors: Stephen Bloom; William Kemp; Amanda Nicoll; Stuart K Roberts; Paul Gow; Anouk Dev; Sally Bell; Siddharth Sood; Ian Kronborg; Virginia Knight; Diana Lewis; John Lubel Journal: J Hepatol Date: 2018-04-28 Impact factor: 25.083
Authors: Julie Parkes; Paul Roderick; Scott Harris; Christopher Day; David Mutimer; Jane Collier; Martin Lombard; Graeme Alexander; John Ramage; Geoffrey Dusheiko; Mark Wheatley; Carol Gough; Alastair Burt; William Rosenberg Journal: Gut Date: 2010-07-30 Impact factor: 23.059
Authors: Arjun N A Jayaswal; Christina Levick; Emmanuel A Selvaraj; Andrea Dennis; Jonathan C Booth; Jane Collier; Jeremy Cobbold; Elizabeth M Tunnicliffe; Matthew Kelly; Eleanor Barnes; Stefan Neubauer; Rajarshi Banerjee; Michael Pavlides Journal: Liver Int Date: 2020-12 Impact factor: 5.828
Authors: Paul Angulo; Elisabetta Bugianesi; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Francisco Barrera; Svanhildur Haflidadottir; Christopher P Day; Jacob George Journal: Gastroenterology Date: 2013-07-13 Impact factor: 22.682
Authors: Christopher R Bradley; Eleanor F Cox; Robert A Scott; Martin W James; Phillip Kaye; Guruprasad P Aithal; Susan T Francis; Indra Neil Guha Journal: J Hepatol Date: 2018-06-08 Impact factor: 25.083